LOGIN  |  REGISTER
Chimerix

Owens & Minor to Present at the BofA Securities 2024 Health Care Conference on May 15, 2024

May 13, 2024 | Last Trade: US$12.00 1.25 -9.43

RICHMOND, Va. / May 13, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer and Jonathan Leon, the Company’s Senior Vice President-Finance and Corporate Treasurer, will be participating in a webcasted fireside chat at 5:20 p.m. Eastern Daylight Time on Wednesday, May 15, 2024 at BofA Securities’ 2024 Health Care Conference in Las Vegas, Nevada. Owens & Minor is also hosting one-on-one meetings with investors at the conference.

Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/ at least 10 minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB